92 related articles for article (PubMed ID: 7780485)
1. Augmentation of specific tumor killing activity by tumor-infiltrating lymphocytes (TIL) in the presence of TNF-SAM2.
Goto S; Suma Y; Noguchi K; Kera J; Sakai S; Soma GI; Takeuchi S
Cancer Biother; 1995; 10(1):37-44. PubMed ID: 7780485
[TBL] [Abstract][Full Text] [Related]
2. Resident research award: tumor necrosis factor alpha selectively enhances growth and cytotoxic activity of tumor infiltrating lymphocytes from human colorectal cancer.
Stolfi VM; Milsom JW; Finke JH; Fazio VW; Fiocchi C
J Surg Res; 1992 Jan; 52(1):39-45. PubMed ID: 1548866
[TBL] [Abstract][Full Text] [Related]
3. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.
Shimizu Y; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Immunol Immunother; 1991; 32(5):280-8. PubMed ID: 1847844
[TBL] [Abstract][Full Text] [Related]
4. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
5. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
Koo AS; Tso CL; Shimabukuro T; Peyret C; deKernion JB; Belldegrun A
J Immunother (1991); 1991 Oct; 10(5):347-54. PubMed ID: 1790142
[TBL] [Abstract][Full Text] [Related]
6. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
7. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
8. T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour-infiltrating lymphocytes (TIL) from melanoma patients.
Pandolfi F; Boyle LA; Trentin L; Oliva A; Kurnick JT
Clin Exp Immunol; 1994 Jan; 95(1):141-7. PubMed ID: 8287599
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
10. Interaction of tumor-infiltrating lymphocyte from oral squamous cell carcinoma with FN enhances its adhesion and cytotoxicity.
Yang H; Li J; Zhao Y; Li Z
Chin J Dent Res; 1999 Dec; 2(3-4):49-53. PubMed ID: 10863417
[TBL] [Abstract][Full Text] [Related]
11. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes.
Mizutani Y; Yoshida O; Miki T
J Urol; 1999 Dec; 162(6):2170-5. PubMed ID: 10569614
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin.
Noguchi K; Tanimura H; Yamaue H; Iwahashi M; Tsunoda T; Tani M; Tamai M; Hotta T; Mizobata S; Arii K
J Cancer Res Clin Oncol; 1997; 123(6):345-51. PubMed ID: 9222301
[TBL] [Abstract][Full Text] [Related]
13. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 augments the generation of autologous tumor-reactive CD8+ cytotoxic T lymphocytes from tumor-infiltrating lymphocytes.
Kuge S; Watanabe K; Makino K; Tokuda Y; Mitomi T; Kawamura N; Habu S; Nishimura T
Jpn J Cancer Res; 1995 Feb; 86(2):135-9. PubMed ID: 7730135
[TBL] [Abstract][Full Text] [Related]
15. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.
Noguchi K; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Tani M; Mizobata S; Hotta T; Arii K; Tamai M
Anticancer Res; 1995; 15(2):255-8. PubMed ID: 7762991
[TBL] [Abstract][Full Text] [Related]
16. Characterization of tumor-necrosis-factor-gene-transduced tumor-infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate, adhesion molecule expression and cytokine production.
Itoh Y; Koshita Y; Takahashi M; Watanabe N; Kohgo Y; Niitsu Y
Cancer Immunol Immunother; 1995 Feb; 40(2):95-102. PubMed ID: 7882388
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
Frost PJ; Belldegrun A; Bonavida B
Prostate; 1999 Sep; 41(1):20-30. PubMed ID: 10440872
[TBL] [Abstract][Full Text] [Related]
18. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
19. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
Frost P; Ng CP; Belldegrun A; Bonavida B
Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
[TBL] [Abstract][Full Text] [Related]
20. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
